Blockade of Cannabinoid Receptor 1 Improves Insulin Resistance, Lipid Metabolism, and Diabetic Nephropathy in db/db Mice

被引:92
作者
Nam, D. H. [1 ]
Lee, M. H. [1 ]
Kim, J. E. [1 ]
Song, H. K. [1 ]
Kang, Y. S. [1 ]
Lee, J. E. [2 ]
Kim, H. W. [2 ]
Cha, J. J. [1 ]
Hyun, Y. Y. [1 ]
Kim, S. H. [3 ]
Han, S. Y. [4 ]
Han, K. H. [4 ]
Han, J. Y. [5 ]
Cha, Dae Ryong [1 ]
机构
[1] Korea Univ, Ansan Hosp, Dept Internal Med, Div Nephrol, Ansan 425020, Kyungki Do, South Korea
[2] Wonkwang Univ, Dept Internal Med, Div Nephrol, Gunpo City 435040, South Korea
[3] Korea Univ, Dept Internal Med, Div Cardiol, Ansan 425020, Kyungki Do, South Korea
[4] Inje Univ, Dept Internal Med, Div Nephrol, Goyang City 411706, South Korea
[5] Inha Univ, Dept Pathol, Inchon 400711, South Korea
基金
新加坡国家研究基金会;
关键词
DIET-INDUCED OBESITY; CB1; ANTAGONISM; FOOD-INTAKE; ENDOCANNABINOID SYSTEM; ENERGY-BALANCE; ADIPOSE-TISSUE; ZUCKER RATS; FA/FA RATS; FATTY-ACID; CHOLESTEROL;
D O I
10.1210/en.2011-1423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The endocannabinoid system is important in the pathogenesis of obesity-related metabolic disorders. However, the effect of inhibiting the endocannabinoid system in type 2 diabetic nephropathy is unclear. Therefore, we examined the effect of the cannabinoid (CB) 1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. Six-week-old db/db mice were treated with the CB1-specific antagonist SR141716 (10 mg/kg.d) for 3 months. Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. Concomitantly, CB1 antagonism improved cardiac functional and morphological abnormality, hepatic steatosis, and phenotypic changes of adipocytes into small differentiated forms, associated with increased adiponectin expression and decreased lipid hydroperoxide levels. CB1 receptor was overexpressed in diabetic kidneys, especially in podocytes. Treatment with the SR141716 markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic and proinflammatory cytokine synthesis. Furthermore, SR141716 improved renal lipid metabolism and decreased urinary 8-isoprostane levels, renal lipid hydroperoxide content, and renal lipid content. In cultured podocytes, high-glucose stimulation increased CB1 receptor expression, and SR141716 treatment abolished high-glucose-induced up-regulation of collagen and plasminogen activator inhibitor-1 synthesis. Additionally, knockdown of CB1 receptor expression by stealth small interfering RNA abolished high-glucose-induced sterol-regulatory element-binding protein-1 expression in podocytes. These findings suggest that CB1 blockade improves insulin resistance and protect against renal injury through both metabolic and antifibrotic effects in type 2 diabetic nephropathy. Targeting CB1 blockade could therefore provide a new therapeutic target to prevent type 2 diabetic nephropathy. (Endocrinology 153: 1387-1396, 2012)
引用
收藏
页码:1387 / 1396
页数:10
相关论文
共 40 条
[1]   Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy [J].
Barutta, Federica ;
Corbelli, Alessandro ;
Mastrocola, Raffaella ;
Gambino, Roberto ;
Di Marzo, Vincenzo ;
Pinach, Silvia ;
Rastaldi, Maria Pia ;
Perin, Paolo Cavallo ;
Gruden, Gabriella .
DIABETES, 2010, 59 (04) :1046-1054
[2]   The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells [J].
Bensaid, M ;
Gary-Bobo, M ;
Esclangon, A ;
Maffrand, JP ;
Le Fur, G ;
Oury-Donat, F ;
Soubrié, P .
MOLECULAR PHARMACOLOGY, 2003, 63 (04) :908-914
[3]   Presence of functional cannabinoid receptors in human endocrine pancreas [J].
Bermudez-Silva, F. J. ;
Suarez, J. ;
Baixeras, E. ;
Cobo, N. ;
Bautista, D. ;
Cuesta-Munoz, A. L. ;
Fuentes, E. ;
Juan-Pico, P. ;
Castro, M. J. ;
Milman, G. ;
Mechoulam, R. ;
Nadal, A. ;
de Fonseca, F. Rodriguez .
DIABETOLOGIA, 2008, 51 (03) :476-487
[4]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[5]   LOWERING THE CHOLESTEROL CONTENT OF MA104 CELLS INHIBITS RECEPTOR-MEDIATED TRANSPORT OF FOLATE [J].
CHANG, WJ ;
ROTHBERG, KG ;
KAMEN, BA ;
ANDERSON, RGW .
JOURNAL OF CELL BIOLOGY, 1992, 118 (01) :63-69
[6]   Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models [J].
Chen, Wei ;
Tang, Huoling ;
Liu, Hongying ;
Long, Long ;
Gong, Zehui ;
Zheng, Jianquan ;
Chi, Mugen ;
Xie, Yunde ;
Zheng, Zhibing ;
Li, Song ;
Wang, Lili .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 637 (1-3) :178-185
[7]  
Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725
[8]   Food Intake-independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism [J].
Cota, Daniela ;
Sandoval, Darleen A. ;
Olivieri, Massimiliano ;
Prodi, Elena ;
D'Alessio, David A. ;
Woods, Stephen C. ;
Seeley, Randy J. ;
Obici, Silvana .
OBESITY, 2009, 17 (08) :1641-1645
[9]  
Dugail I, 2003, HORM METAB RES, V35, P204, DOI 10.1055/s-2003-39475
[10]   Low-grade systemic inflammation and the development of type 2 diabetes - The atherosclerosis risk in communities study [J].
Duncan, BB ;
Schmidt, MI ;
Pankow, JS ;
Ballantyne, CM ;
Couper, D ;
Vigo, A ;
Hoogeveen, R ;
Folsom, AR ;
Heiss, G .
DIABETES, 2003, 52 (07) :1799-1805